Puma Biotechnology Inc PBYI

Puma Biotechnology Inc. is an American biopharmaceutical company, which has its corporate headquarters in Los Angeles, California, and is incorporated in Delaware. The company is engaged in the development and commercialisation of a range of solutions aimed primarily at cancer patients across the United States and throughout the world. The firm was founded in 2010.

The firm is predominantly focused on acquiring and developing innovative biopharmaceutical products for the treatment of various forms of cancer. The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing, and then seeks to further develop those drug candidates for commercial use.

The firm’s has a strong focus on breast cancers, and current drug candidates include PB272 for the adjuvant treatment of adult patients with early stage HER2-overamplified breast cancer, PB272 for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer and PB272 for HER2 mutation-positive solid tumours. The company’s common stock began trading in 2012. The firm is now listed on the NASDAQ where it trades under the stock ticker PBYI.

Monitor the Puma Biotechnology Inc. share price by adding it to your eToro watchlist, to get instant news and updates on PBYI stock value changes.